Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Snoring may indicate future health risks

Snoring may indicate future health risks

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

Polypill could reduce CVD and stroke in Latin Americans by up to 21% at lower cost

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam advances Tuschl II patent estate through the USPTO

Lupin’s Fenofibrate tablets now available in the U.S.

Lupin’s Fenofibrate tablets now available in the U.S.

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Monoclonal antibody boosts cholesterol reduction

Monoclonal antibody boosts cholesterol reduction

Treatment with AMG 145 reduces LDL cholesterol

Treatment with AMG 145 reduces LDL cholesterol

Monoclonal antibody boosts cholesterol reduction

Monoclonal antibody boosts cholesterol reduction

Traditional CV risk factors linked to peripheral artery disease

Traditional CV risk factors linked to peripheral artery disease

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam third quarter 2012 revenues decrease to $16.8 million

Smoke-free laws lead to fewer heart attacks

Smoke-free laws lead to fewer heart attacks

Traditional CV risk factors linked to peripheral artery disease

Traditional CV risk factors linked to peripheral artery disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.